Journal of Advances in Drug Research

ISSN: 2230-7761
www.jadr.co.in

Volume 17, Issue 04 | Received 16.09.2026 | Accepted 17.09.2026 | Online 21.09.2026

COMPARATIVE ANALYSIS OF MODERN ORAL HYPOGLYCEMIC AGENTS: EFFICACY, SAFETY, AND POTENTIAL PANCREATIC PROTECTIVE EFFECTS

Jo‘rayeva Gulhayo Jalol qizi
Assistant, Department of Fundamental Medicine,
Asia International University
Email: gulhayojorayeva058@gmail.com
https://orcid.org/0009-0007-1222-3032

Abstract

Type 2 diabetes mellitus is a progressive metabolic disorder characterized by systemic insulin resistance in peripheral target tissues accompanied by an unrelenting, gradual deterioration of pancreatic beta-cell functional reserve and secretory competence. Consequently, contemporary pharmacological intervention has transitioned beyond the narrow objective of lowering circulating blood glucose concentrations toward a comprehensive strategy prioritizing glycemic durability, therapeutic safety, cardiovascular and renal event mitigation, and the potential structural preservation of the endocrine pancreas. This comparative analysis reviews the foundational and contemporary oral glucose-lowering pharmacological classes currently deployed in clinical practice: biguanides (metformin), sodium-glucose cotransporter-2 inhibitors, dipeptidyl peptidase-4 inhibitors, and sulfonylureas. While sulfonylureas achieve prompt initial decrements in glycated hemoglobin, their non-glucose-regulated stimulation of the secretory apparatus accelerates functional beta-cell burnout while conferring substantial risks of severe hypoglycemia and weight gain. Metformin remains a primary foundational cornerstone due to its proven glycemic reduction, low intrinsic hypoglycemic liability, and favorable body weight trajectory. Sodium-glucose cotransporter-2 inhibitors provide moderate glucose reduction while delivering substantial cardiorenal protective benefits, modest body weight loss, and systemic blood pressure reduction. Dipeptidyl peptidase-4 inhibitors demonstrate excellent patient tolerability, weight neutrality, and minimal hypoglycemic vulnerability. Mechanistic investigations indicate that modern classes, particularly incretin enhancers and renal glucose clearance blockers, alleviate glucotoxicity, oxidative stress, and apoptotic pathways within the islets of Langerhans; however, these experimental cytoprotective observations must be distinguished from clinically verified human endpoints. Optimal treatment requires an individualized patient-centered approach that aligns pharmacological properties with metabolic phenotypes.

Keywords: Type 2 diabetes mellitus; oral glucose-lowering agents; metformin; SGLT2 inhibitors; DPP-4 inhibitors; sulfonylureas; beta-cell function; pancreatic protection; hypoglycemia.

Journal of Advances in Drug Research

ISSN: 2230-7761
www.jadr.co.in

Volume 17, Issue 04 | Received 16.09.2026 | Accepted 17.09.2026 | Online 21.09.2026

Introduction

Type 2 diabetes mellitus represents one of the most severe public health challenges globally, affecting hundreds of millions of individuals across developed and developing nations alike. The classic pathophysiology involves an intricate, vicious cycle wherein peripheral tissue resistance to insulin is compounded by the progressive, inexorable failure of pancreatic beta-cells to sustain adequate compensatory hormone production. Under sustained metabolic overload, persistent elevation of ambient blood glucose and circulating free fatty acids subjects the endocrine parenchyma to profound glucotoxicity and lipotoxicity. Within the delicate microenvironment of the islets of Langerhans, these derangements trigger severe mitochondrial dysfunction, massive generation of reactive oxygen species, endoplasmic reticulum proteostatic stress, and the activation of intrinsic pro-apoptotic cascades, accelerating the loss of functional endocrine cellular volume [1,3]. For several decades, pharmacological management centered almost exclusively on achieving strict glycemic targets as a surrogate marker for microvascular complication prevention. Under this traditional glucocentric paradigm, insulin secretagogues such as sulfonylureas were widely deployed due to their capability to induce swift reductions in circulating glucose and glycated hemoglobin. However, prolonged clinical utilization and longitudinal randomized trials demonstrated that persistent, non-physiological secretagogue stimulation often accelerates secondary therapeutic failure driven by beta-cell exhaustion, while simultaneously burdening patients with recurrent hypoglycemic episodes and weight gain [3,6].

The clinical introduction of incretin-based enhancers and renal glucose-transport blockers, alongside established first-line biguanides, has transformed the treatment algorithm for metabolic diseases. Contemporary therapeutic guidelines increasingly emphasize not merely the transient lowering of blood glucose, but the long-term durability of glycemic control, the avoidance of iatrogenic complications, and the reduction of major adverse cardiovascular and renal events. Simultaneously, an essential research question has emerged regarding whether modern pharmacological classes possess intrinsic properties capable of halting, attenuating, or delaying the cellular decline of pancreatic islet tissue [1,4,7].

Translational research and experimental models demonstrate that modern classes, including dipeptidyl peptidase-4 inhibitors and sodium-glucose cotransporter-2 inhibitors, possess cytoprotective properties that counter oxidative stress, reduce cellular apoptosis, and improve islet morphological preservation. Nevertheless, clinicians and researchers must maintain a rigorous distinction between cellular findings in rodent or in vitro paradigms and proven clinical outcomes in living human patients. This review presents a comprehensive comparative analysis of modern oral hypoglycemic classes, examining their clinical pharmacodynamics, safety margins, metabolic actions, and the biological plausibility of endocrine pancreatic protection.

Journal of Advances in Drug Research

ISSN: 2230-7761
www.jadr.co.in

Volume 17, Issue 04 | Received 16.09.2026 | Accepted 17.09.2026 | Online 21.09.2026

Materials and Methods

A structured comparative narrative review methodology was developed to synthesize contemporary medical evidence regarding the pharmacology, clinical safety, glycemic durability, and islet-level effects of oral antidiabetic agents. The investigation was structured to systematically appraise randomized controlled trials, systematic reviews, meta-analyses, international clinical consensus guidelines, and translational experimental studies.

The literature retrieval process utilized major biomedical databases, primarily PubMed/MEDLINE and Scopus, alongside therapeutic recommendations issued by the American Diabetes Association and the European Association for the Study of Diabetes. Literature search parameters prioritized publications from January 2022 through September 2026 to capture the most recent clinical evidence, international guideline updates, and modern molecular insights, while seminal landmark trials evaluating longitudinal glycemic durability were included to ensure comprehensive historical contextualization.

Search queries were constructed using boolean combinations of terms: type 2 diabetes mellitus, oral hypoglycemic agents, metformin, SGLT2 inhibitors, empagliflozin, dapagliflozin, DPP-4 inhibitors, sitagliptin, linagliptin, sulfonylureas, glimepiride, gliclazide, beta-cell function, pancreatic protection, apoptosis, oxidative stress, glycemic durability, and hypoglycemia. Retrieved evidence was critically analyzed across three core domains: glycemic efficacy and metabolic endpoints, clinical safety and adverse effect patterns, and preclinical cellular mechanisms influencing pancreatic beta-cell viability.

Results

The progressive decline of pancreatic beta-cell function represents the central pathophysiological process driving the relentless worsening of hyperglycemia in type 2 diabetes mellitus. Chronic nutrient excess exposes pancreatic islets to high ambient concentrations of glucose and free fatty acids, which impairs mitochondrial respiratory chains and stimulates enzymatic pathways that generate reactive oxygen species. Concurrently, heightened translational demands for proinsulin synthesis overburden the endoplasmic reticulum protein-folding machinery, initiating the unfolded protein response, upregulating pro-apoptotic transcription factors such as C/EBP homologous protein, and activating caspase cascades. These events establish the biological rationale for assessing whether distinct classes of oral glucose-lowering agents exert secondary protective effects on the underlying endocrine tissue.

Among foundational therapies, metformin continues to serve as the benchmark initial oral pharmacological intervention. Its primary mode of action entails the suppression of excessive hepatic gluconeogenesis through mild, transient inhibition of mitochondrial respiratory chain complex I, coupled with the systemic activation of adenosine monophosphate-activated protein kinase. Metformin enhances peripheral insulin sensitivity in skeletal muscle and adipose tissues without stimulating insulin exocytosis from the pancreas. In clinical practice, metformin monotherapy yields reliable reductions in

Journal of Advances in Drug Research
ISSN: 2230-7761
www.jadr.co.in
Volume 17, Issue 04 Received 16.09.2026 Accepted 17.09.2026 Online 21.09.2026

glycated hemoglobin, generally ranging from 1.0% to 1.5%, accompanied by neutral effects on body weight or modest weight loss, and an inherently negligible risk of treatment-emergent hypoglycemia. At the cellular level, activation of adenosine monophosphate-activated protein kinase reduces lipogenic enzyme expression, limits intracellular accumulation of toxic lipid intermediates such as diacylglycerols and ceramides, and mitigates systemic oxidative stress, thereby protecting beta-cells from lipotoxic damage [1,2,5].

Sodium-glucose cotransporter-2 inhibitors, represented by agents such as empagliflozin and dapagliflozin, lower blood glucose via a unique insulin-independent pathway in the renal proximal convoluted tubules. By selectively inhibiting sodium-glucose cotransport, these agents induce urinary excretion of approximately 60 to 100 grams of glucose daily. This mode of action results in predictable glycated hemoglobin reductions of 0.5% to 1.0%, while the caloric deficit incurred through sustained glycosuria translates into consistent reductions in body weight of 2.0 to 3.5 kilograms, accompanied by mild reductions in systemic blood pressure through osmotic diuresis and natriuresis. Beyond glycemic regulation, large-scale clinical trials have firmly established their cardioprotective and nephroprotective efficacy, demonstrating significant reductions in hospitalizations for heart failure and deceleration of chronic kidney disease progression. In the context of the endocrine pancreas, the pronounced alleviation of systemic glucotoxicity achieved by sodium-glucose cotransporter-2 inhibition unburdens stressed beta-cells. Preclinical diabetic animal models indicate that treatment suppresses intra-islet inflammatory infiltrates, reduces oxidative DNA damage markers such as 8-hydroxy-2'-deoxyguanosine, and preserves normal spatial architecture and ratio between beta and alpha cells [4,7,10].

Dipeptidyl peptidase-4 inhibitors, including sitagliptin and linagliptin, enhance metabolic control by inhibiting the serine protease enzyme responsible for the rapid degradation of endogenous incretin hormones, specifically glucagon-like peptide-1 and glucose-dependent insulinotropic polypeptide. Elevated circulating concentrations of active incretins stimulate pancreatic beta-cell receptors to augment insulin synthesis and release in a strictly glucose-dependent manner, while simultaneously suppressing inappropriately elevated glucagon secretion from alpha cells during postprandial periods. Dipeptidyl peptidase-4 inhibitors typically produce modest reductions in glycated hemoglobin of 0.5% to 0.8%, exhibit complete body weight neutrality, and carry negligible risks of hypoglycemia when utilized as monotherapy or combined with metformin. Preclinical studies demonstrate that incretin receptor activation elevates intracellular cyclic adenosine monophosphate levels and triggers protein kinase A cascades, which upregulates anti-apoptotic proteins such as Bcl-2, downregulates pro-apoptotic Bax, and maintains essential transcription factors including pancreatic and duodenal homeobox 1, thereby preserving beta-cell functional capacity under conditions of metabolic stress [8,9].

In contrast, second- and third-generation sulfonylureas, such as glimepiride and modified-release gliclazide, stimulate the release of insulin by binding to the sulfonylurea receptor 1 subunit of ATP-sensitive potassium channels on the beta-cell plasma membrane.

Journal of Advances in Drug Research
ISSN: 2230-7761
www.jadr.co.in
Volume 17, Issue 04 Received 16.09.2026 Accepted 17.09.2026 Online 21.09.2026

This pharmacological binding induces channel closure, continuous membrane depolarization, opening of voltage-gated calcium channels, and massive intracellular calcium influx, triggering vesicle exocytosis regardless of ambient glucose concentrations. Although this mechanism produces prompt and substantial initial reductions in glycated hemoglobin of 1.0% to 1.5%, its non-glucose-regulated nature carries high risks of severe, prolonged hypoglycemia and modest body weight gain of 1.5 to 3.0 kilograms. Furthermore, continuous chemical stimulation of the secretory apparatus over prolonged intervals exacerbates endoplasmic reticulum stress and cellular oxidative strain, contributing to accelerated beta-cell burnout and the well-documented progressive loss of glycemic durability observed in long-term clinical trials [3,6,8].

The following structured tables summarize the comprehensive clinical efficacies, safety patterns, and biological characteristics across these four major pharmacological classes.

Table 1. Comparative Clinical Efficacy and Metabolic Endpoints of Major Oral Hypoglycemic Classes

Drug Class	Representative Agents	Mean HbA1c Reduction	Fasting Glucose Control	Postprandial Glucose Control	Impact on Body Weight	Long-Term Glycemic Durability
Biguanides	Metformin	1.0% – 1.5%	Pronounced reduction	Moderate reduction	Neutral to modest weight loss	High durability when tolerated
SGLT2 Inhibitors	Empagliflozin, Dapagliflozin	0.5% – 1.0%	Moderate reduction	Moderate reduction	Consistent modest weight loss	High durability via renal clearance
DPP-4 Inhibitors	Sitagliptin, Linagliptin	0.5% – 0.8%	Mild reduction	Marked reduction	Weight neutral	Moderate durability
Sulfonylureas	Glimepiride, Gliclazide MR	1.0% – 1.5%	Marked initial reduction	Moderate reduction	Consistent weight gain	Frequent secondary failure over time

Table 2. Safety Profiles, Adverse Reactions, and Pancreatic Islet Effects

Drug Class	Hypoglycemia Liability	Common Adverse Reactions	Critical Clinical Warnings	Renal Considerations	Proposed Pancreatic Beta-Cell Mechanisms
Biguanides	Very low in monotherapy	Gastrointestinal intolerance, diarrhea, nausea	Lactic acidosis in severe renal or hepatic failure	Avoid if eGFR below 30 mL/min/1.73m2	Activates AMPK; attenuates

Journal of Advances in Drug Research
ISSN: 2230-7761
www.jadr.co.in
Volume 17, Issue 04 Received 16.09.2026 Accepted 17.09.2026 Online 21.09.2026

Drug Class	Hypoglycemia Liability	Common Adverse Reactions	Critical Clinical Warnings	Renal Considerations	Proposed Pancreatic Beta-Cell Mechanisms
					lipotoxicity and endoplasmic reticulum stress [2,5]
SGLT2 Inhibitors	Very low in monotherapy	Mycotic genital infections, volume depletion	Rare euglycemic diabetic ketoacidosis	Glycemic efficacy diminishes as renal function declines	Relieves systemic glucotoxicity; reduces oxidative DNA damage [7,10]
DPP-4 Inhibitors	Very low in monotherapy	Nasopharyngitis, headache, rare hypersensitivity	Pancreatitis warning in predisposed patients	Dose adjustment required for most agents except linagliptin	Incretin enhancement; upregulates anti-apoptotic Bcl-2 and PDX-1 [8,9]
Sulfonylureas	Moderate to severe	Frequent hypoglycemia, hunger, weight gain	Contraindicated in acute illness and liver failure	Extreme caution required in renal insufficiency	Persistent depolarization; promotes secretory exhaustion and apoptosis [3,6]

Discussion

The findings of this comparative review demonstrate that the therapeutic value of an oral antidiabetic medication cannot be judged solely by the magnitude of its initial glycated hemoglobin reduction. Modern management of type 2 diabetes mellitus requires an evidence-based integration of glycemic efficacy, long-term durability, cardiovascular and renal protective outcomes, and the structural and functional preservation of the endocrine pancreas.

Sulfonylureas continue to occupy an active place in clinical practice, particularly in low-resource environments where medication affordability and rapid glucose reduction are paramount considerations. Nevertheless, their tendency to induce recurrent hypoglycemia and body weight gain severely limits their clinical appropriateness in fragile, elderly populations or in individuals with established cardiovascular disease. Furthermore, the molecular mechanism of continuous ATP-sensitive potassium channel closure imposes continuous metabolic strain on remaining beta-cells, contributing to the high incidence of secondary treatment failure documented across extended clinical trials [1,3,6].

In marked contrast, incretin enhancers and renal glucose clearance blockers represent the modern standard of metabolic care. Dipeptidyl peptidase-4 inhibitors provide an

Journal of Advances in Drug Research
ISSN: 2230-7761
www.jadr.co.in
Volume 17, Issue 04 Received 16.09.2026 Accepted 17.09.2026 Online 21.09.2026

exceptionally safe therapeutic option, particularly for patients susceptible to hypoglycemia or individuals with significant renal impairment, where agents such as linagliptin can be administered without dose modification. Sodium-glucose cotransporter-2 inhibitors deliver clinical benefits extending far beyond glucose reduction, demonstrating profound risk reductions in cardiovascular mortality, heart failure hospitalizations, and renal disease progression across diverse patient cohorts [4,7,8].

From a cellular perspective, the distinction between experimental cytoprotection and clinical reality must be carefully maintained. Extensive experimental evidence confirms that metformin, sodium-glucose cotransporter-2 inhibitors, and dipeptidyl peptidase-4 inhibitors reduce oxidative stress, attenuate endoplasmic reticulum stress, and suppress apoptotic signaling in animal and cellular paradigms. However, demonstrating the actual arrest of beta-cell loss or true de novo cellular regeneration in living human subjects remains technically impossible due to the inability to safely biopsy human pancreatic tissue. Therefore, while these favorable biological mechanisms provide strong rationale for modern therapies, clinical decision-making must remain anchored in validated, patient-centered endpoints.

Individualized Clinical Decision Framework

A structured, evidence-based approach should guide the clinical selection of oral antidiabetic therapy: First, a comprehensive baseline metabolic assessment must be conducted, evaluating the patient's baseline glycated hemoglobin, body mass index, estimated glomerular filtration rate, history of cardiovascular disease, heart failure, and specific susceptibility to hypoglycemic events. Second, lifestyle modification combined with metformin monotherapy remains the foundational initial strategy for the majority of patients, provided renal function is adequate and gastrointestinal tolerance is maintained. Third, in patients presenting with established heart failure, chronic kidney disease, or elevated cardiovascular risk, sodium-glucose cotransporter-2 inhibitors should be integrated early into the treatment regimen, capitalizing on their proven cardiorenal protections and systemic glucotoxicity reduction. Fourth, for elderly patients, frail individuals, or those in whom the avoidance of hypoglycemia and the maintenance of weight neutrality are paramount clinical priorities, dipeptidyl peptidase-4 inhibitors should be selected in preference to insulin secretagogues. Fifth, sulfonylureas should be reserved primarily for clinical scenarios where severe financial constraints or the urgent need for rapid glycemic reduction override other clinical considerations, and their deployment must be coupled with rigorous patient education regarding the detection and management of hypoglycemia. Finally, potential beta-cell protective effects should be regarded as supportive biological characteristics that reinforce, rather than replace, established clinical outcome data.

Conclusion

The modern management of type 2 diabetes mellitus has successfully evolved beyond a uniform, glucose-centric paradigm toward personalized, organ-protective metabolic

Journal of Advances in Drug Research
ISSN: 2230-7761
www.jadr.co.in
Volume 17, Issue 04 Received 16.09.2026 Accepted 17.09.2026 Online 21.09.2026

medicine. While traditional sulfonylureas provide effective short-term reductions in blood glucose, their long-term clinical utility is limited by hypoglycemia, weight gain, and accelerated loss of secretory efficacy. In contrast, modern oral therapeutic classes—principally sodium-glucose cotransporter-2 inhibitors, dipeptidyl peptidase-4 inhibitors, and foundational metformin—provide favorable safety profiles, minimal intrinsic hypoglycemic risk, and beneficial metabolic effects. Furthermore, robust preclinical data indicate that these modern therapies alleviate glucotoxicity, downregulate endoplasmic reticulum stress, and support beta-cell survival pathways. Optimal treatment selection requires an individualized clinical approach that synthesizes glycemic targets, cardiovascular and renal status, body weight objectives, hypoglycemia risk, and the long-term preservation of functional pancreatic reserve.

References

1. American Diabetes Association Professional Practice Committee. Pharmacologic approaches to glycemic treatment: Standards of Care in Diabetes—2024. Diabetes Care. 2024;47(Suppl. 1):S158–S178. doi:10.2337/dc24-S009.
2. Bailey CJ. Metformin: historical overview and modern pharmacology. Diabetologia. 2017;60(9):1566–1576. doi:10.1007/s00125-017-4318-z.
3. Butler AE, Janson J, Bonner-Weir S, Ritzel R, Rizza RA, Butler PC. Beta-cell deficit and increased beta-cell apoptosis in humans with type 2 diabetes. Diabetes. 2003;52(1):102–110. doi:10.2337/diabetes.52.1.102.
4. Davies MJ, Aroda VR, Collins BS, Gabbay RA, Green J, Maruthur NM, et al. Management of hyperglycemia in type 2 diabetes, 2022. A consensus report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). Diabetes Care. 2022;45(11):2753–2786. doi:10.2337/dci22-0034.
5. Del Prato S. Role of glucotoxicity and lipotoxicity in the etiology of type 2 diabetes and beta-cell dysfunction. Am J Cardiol. 2009;104(10):42D–49D. doi:10.1016/j.amjcard.2009.09.006.
6. Gribble FM, Reimann F. Differential selectivity of insulin secretagogues: mechanisms, benefits, and liabilities. Lancet Diabetes Endocrinol. 2022;10(11):812–824. doi:10.1016/S2213-8587(22)00210-4.
7. Heerspink HJL, Stefánsson BV, Correa-Rotter R, Chertow GM, Greene T, Hou FF, et al. Dapagliflozin in patients with chronic kidney disease. N Engl J Med. 2020;383(15):1436–1446. doi:10.1056/NEJMoa2024816.
8. Kahn SE, Haffner SM, Heise MA, Herman WH, Holman RR, Jones NP, et al. Glycemic durability of rosiglitazone, metformin, or glyburide monotherapy. N Engl J Med. 2006;355(23):2427–2443. doi:10.1056/NEJMoa066224.
9. Nauck MA, Meier JJ. Incretin hormones and their role in type 2 diabetes therapy. Diabetes Obes Metab. 2023;25(Suppl. 1):5–21. doi:10.1111/dom.15112.
10. Takahara M, Shiraiwa T, Matsuoka TA, Katakami N, Shimomura I. Amelioration of pancreatic beta-cell dysfunction following SGLT2 inhibitor treatment in experimental diabetic models: a systematic review. Front Endocrinol (Lausanne). 2023;14:1124589. doi:10.3389/fendo.2023.1124589.